Generation of Novel Biotherapeutic (UCD3R) to Repair, Restore and Regenerate Epithelial and Neuronal Systems

Abstract

Researchers at the University of California, Davis have developed a novel hybrid microbial-derived oxylipin and endocannabinoid-like molecule designed to enhance gut and brain health by improving barrier integrity, reducing inflammation, and providing neuroprotection.

Full Description

This technology centers on 10-hydroxystearoylethanolamide (UCD3R), a synthesized compound combining the microbial oxylipin 10-hydroxystearic acid (10-HSA) with an ethanolamine moiety, inspired by the endocannabinoid-like oleoylethanolamide (OEA). This structural modification enhances lipophilicity, absorption, systemic bioavailability, and blood-brain barrier permeability while preserving and amplifying PPARα-mediated beneficial effects. UCD3R promotes gut epithelial repair, strengthens tight junction protein expression, induces epigenetic modifications linked to mitochondrial function, and offers neuroprotective effects outperforming its precursor 10-HSA in inflamed neuronal models. By bridging microbial bioactive lipid signaling with endocannabinoid pathways, UCD3R targets gut-brain axis restoration for a range of disorders related to inflammation, metabolic dysfunction, cognitive decline, and neurodegeneration.

Applications

• Treatment of inflammatory bowel diseases and gut barrier dysfunction. 
• Therapies for neurodegenerative diseases and cognitive decline involving neuroinflammation. 
• Metabolic disorder management including obesity and insulin resistance. 
• Adjunctive therapies for mood disorders, addiction, and behavioral health conditions via gut-brain axis modulation. 
• Development of nutritional supplements and pharmaceuticals leveraging bioactive dietary fatty acids. 
• Supportive treatments for viral gut inflammation and associated immune dysfunction.

Features/Benefits

• Enhances intestinal absorption and systemic bioavailability compared to traditional microbial oxylipins like 10-HSA. 
• Crosses the blood-brain barrier to provide direct neuroprotective effects. 
• Potently activates PPARα receptor pathways, supporting anti-inflammatory activity and mitochondrial health. 
• Improves gut barrier integrity by upregulating tight junction proteins such as ZO1. 
• Exerts epigenetic effects via histone crotonylation for sustained gene regulation. 
• Simultaneously targets gut and brain tissues, supporting holistic treatment of gut-brain axis disorders. 
• Derived from natural bioactive fatty acids, ensuring biocompatibility. 
• Overcomes poor absorption and limited blood-brain barrier penetration of prior bioactive compounds. 
• Alleviates gut barrier damage, inflammation, neuroinflammation, and neuronal injury in systemic and neurological diseases. 
• Expands therapeutic strategies by providing options that target both gut and brain dysfunction at once.

Patent Status

Patent Pending